Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

Table 1 Summary of positioning of natalizumab in the paradigm of MS therapies

Indication	Clinically isolated syndrome	Relapsing-remitting MS
Escalation therapy		Natalizumab
		Fingolimod (depending on other risk factors: anti-JCV antibody status, diabetes mellitus, cardiac problems)
		Failure to other treatments (e.g. mitoxantrone, cyclophosphamide)
Baseline therapy	Glatiramer acetate	Glatiramer acetate	Highly active patients:
	Interferon	Interferon	Natalizumab
	Interferon	Interferon	Fingolimod

ISSN: 1471-2377